文献速递肺血管病与心包/心肌炎心力衰竭与心肌病

左心疾病相关肺动脉高压:挑战、新兴策略与未来方向

Pulmonary Hypertension Associated With Left Heart Disease: Challenges, Emerging Strategies, and Future Directions.
PubMed 文献 · J Am Coll Cardiol · 2026-03-11

该综述聚焦于左心疾病相关肺动脉高压(PH-LHD),指出其是最常见的肺动脉高压类型,与显著发病和死亡风险相关,诊断因表型重叠、超声心动图估测不精确及依赖有创血流动力学评估而具有挑战性。肺动脉高压药物在该人群中未显示获益甚至可能有害,目前除针对基础左心疾病的治疗外,尚无专门获批的药物或介入疗法。多种药物(如sotatercept、松弛素类似物、左西孟旦)及器械策略(肺动脉去神经术、经导管心房分流、心包切开术)正在研究中,但临床试验进展受患者招募、表型异质性及缺乏标准化功能和血流动力学终点所阻碍。

要点

  • PH-LHD是最常见的肺动脉高压类型,与高发病率和死亡风险相关。
  • 肺动脉高压药物在PH-LHD中未显示获益,甚至可能有害。
  • 目前除治疗基础左心疾病外,无专门获批的PH-LHD药物或介入疗法。

核心结论

  • PH-LHD是最常见的肺动脉高压类型,与显著发病和死亡风险相关,但目前除针对基础左心疾病的治疗外,尚无专门获批的疗法。

研究设计与样本

  • 综述总结了关于左心疾病相关肺动脉高压的当前知识、新兴药物与侵入性疗法、试验设计与监管审批的障碍,并提出未来研究框架。

主要发现

  • 肺动脉高压药物在PH-LHD人群中未显示获益,甚至可能有害。
  • 多种药物(sotatercept、松弛素类似物、左西孟旦)和器械策略(肺动脉去神经术、经导管心房分流、心包切开术)正在研究中。
  • 临床试验进展受患者招募、表型异质性及缺乏标准化功能和血流动力学终点所阻碍。

临床怎么用

  • 临床应针对基础左心疾病进行治疗,避免使用未证实获益的肺动脉高压药物。

局限性

  • PH-LHD诊断因表型重叠、超声心动图估测不精确及依赖有创血流动力学评估而具有挑战性。
  • 临床试验进展受患者招募、表型异质性及缺乏标准化功能和血流动力学终点所阻碍。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pulmonary hypertension (PH) associated with left heart disease (LHD) is the most prevalent form of PH and is associated with substantial morbidity and mortality risk. Diagnosis is challenging because of overlapping phenotypes, imprecise echocardiographic estimates, and reliance on invasive hemodynamic assessment. Pulmonary arterial hypertension drugs have shown no benefit and may even be harmful in this population. There are no pharmacologic or interventional therapies approved specifically for PH-LHD to date, other than treatments directed at the underlying LHD. Multiple pharmacologic agents, such as sotatercept, relaxin analogues, and levosimendan, along with device-based strategies such as pulmonary artery denervation, transcatheter atrial shunts, and pericardiotomy, are under investigation. Progress in clinical trials has been hindered by patient recruitment, phenotypic heterogeneity, and a lack of standardized functional and hemodynamic outcomes. This review summarizes the current knowledge on PH-LHD, highlights emerging pharmacologic and invasive therapies, discusses barriers to trial design and regulatory approval, and proposes a framework to guide future investigations.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Khan MS, Borlaug BA, Butler J, et al. Pulmonary Hypertension Associated With Left Heart Disease: Challenges, Emerging Strategies, and Future Directions. J Am Coll Cardiol. 2026. PMID: 41811276. doi:10.1016/j.jacc.2026.01.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。